


Appl. No. : 10/661,296
Filed : September 12, 2003

REMARKS

The Examiner has required restriction to one of the Groups I-XII inventions. Applicants elect, without traverse, to prosecute the claims directed to Group I, including Claims 1-17 that are drawn to compounds with one of the Q, T, X and Z being N. Applicants hereby elect Compound S-5 as the single disclosed species, and its structure is shown below:



Claims 18-46 have been withdrawn for directing to non-elected subject matter. Furthermore, Claims 18, 25, 28 and 39-46 have also been amended to depend from Claim 1. Applicants respectfully request that the restricted claims be rejoined upon the allowance of the product claims in accordance with M.P.E.P § 821.04. Applicants also reserve the right to pursue the restricted subject matters in subsequent divisional application(s).

Claims 1-4 and 6-17 have been amended to recite compounds *per se*. Claims 47-48, which depend from Claim 1, have been added and are directed to pharmaceutical composition. Claim 49 has also been added and is directed to a preferred embodiment of the invention. Support for the amendment and new claims can be found throughout the Specification and Claims as filed, therefore no new matter is being added herewith. Claim 5 has been cancelled. Accordingly, Claims 1-4, 6-17 and 47-49 are currently pending.


Appl. No. : **10/661,296**
Filed : **September 12, 2003**

Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned at telephone number appearing below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/10/06

By: 
Agnes Juang, Ph.D.
Registration No. 55,310
Attorney of Record
Customer No. 20,995
(949) 760-0404

2985556_2
101006